Amgen ends marketing agreement with GSK for osteoporosis drug
April 03, 2014 at 09:58 AM EDT
April 3 (Reuters) - Amgen Inc said it was ending an agreement with GlaxoSmithKline Plc, under which the British company marketed Amgen's postmenopausal osteoporosis drug in some regions outside the United States.